Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribozyme gene therapy for HIV-related non-Hodgkin's lymphoma
NCT00002221Phase 2Completed
- Sponsor
- Ribozyme Pharmaceuticals
- Modality
- Gene Editing, Gene Silencing, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-HIV-1 tat ribozyme in non-Hodgkin lymphoma (NHL) and human immunodeficiency virus infection (HIV), sponsored by Ribozyme Pharmaceuticals. Primary endpoint: Safety and tolerability of ribozyme-transduced stem cell infusion at 24 months. Status: completed.
02
Drugs
anti-HIV-1 tat ribozyme
03
Conditions
non-Hodgkin lymphoma (NHL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002221.